Items where Subject is "RC0254 Neoplasms. Tumors. Oncology (including Cancer)"

Library of Congress subjects (102130) R Medicine (9801) RC Internal medicine (591) RC0254 Neoplasms. Tumors. Oncology (including Cancer) (62)
Number of items at this level: 62.
2026
  • Shahzad, Mahnum, DuBois, Steven G, Costa, Rebecca, Argetsinger, Stephanie, Ross-Degnan, Dennis, Bourgeois, Florence T, Wagner, Anita K (2026). Assessment of oral anticancer medicines in pediatric patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021. Journal of Pediatrics, 290, https://doi.org/10.1016/j.jpeds.2025.114949
    • 2025
  • GBD 2023 Cancer Collaborators (2025). The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 406(10512), 1565 - 1586. https://doi.org/10.1016/S0140-6736(25)01635-6
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanavos, Panos (2025). HTA54 Beyond RCTs the role of patient perspectives and nontraditional evidence in HTA decisions for breast cancer (BC) and non-small cell lung cancer (NSCLC). Value in Health, 28(12, Supplement 1), S411. https://doi.org/10.1016/j.jval.2025.09.1839
  • Alani, Ahmad Hecham, Sharma, Abhinaw, Chellani, Lehar, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA27 Advocating from the margins: how patient input aligns with broader evidence tolerance in HTA within oncology. Value in Health, 28(12, Supplement 1), S405. https://doi.org/10.1016/j.jval.2025.09.1812
  • Bedia, Jacob S., Jacobs, Ian J., Ryan, Andy, Gentry-Maharaj, Aleksandra, Burnell, Matthew, Singh, Naveena, Manchanda, Ranjit, Kalsi, Jatinderpal K., Dawnay, Anne & Fallowfield, Lesley et al (2025). Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS. EBioMedicine, 112, https://doi.org/10.1016/j.ebiom.2024.105554 picture_as_pdf
  • Benjamin, D.J., Jenei, Kristina, Lythgoe, M.P. (2025). 2275O The global medical oncology workforce, 2025: disparities in access to care. Annals of Oncology, 36(Supplement 2), S1255 - S1256. https://doi.org/10.1016/j.annonc.2025.08.2891
  • Cheng, Mark T.K., Morris, James S., Shah, Syed F.H., Tolley, Abraham, Chen-Xu, José, Sogandji, Nihal, Fong, Long H., Irodi, Anushka, Chan, Justine T.N. & Kamelian, Kimia et al (2025). Determinants of SARS-CoV-2 outcomes in patients with cancer vs controls without cancer: a multivariable meta-analysis with genomic imputation. EClinicalMedicine, 83, https://doi.org/10.1016/j.eclinm.2025.103194 picture_as_pdf
  • Cherla, Avi, Woloshin, Steven, Wagner, Anita K., Wouters, Olivier J., Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). New cancer drug approvals: less than half of important clinical trial uncertainties reported by the FDA to clinicians, 2019–22. Health Affairs, 44(7), 830 - 838. https://doi.org/10.1377/hlthaff.2024.01134 picture_as_pdf
  • Civitelli, Diego, Therianos, Panagiotis, Gill, Jennifer, Kanavos, Panos (2025). HTA222 Life-years lost due to regulatory and reimbursement delays: a study of oncology drugs across England, Scotland, and France, 2022-2024. Value in Health, 28(12, Supplement 1), S448. https://doi.org/10.1016/j.jval.2025.09.2006
  • Ecker, Hanne, Liang, Ava (2025). EE163 Cost-effectiveness analysis of ribociclib with endocrine therapy for treatment with premenopausal women with HR positive HER2 negative early breast cancer in the UK. Value in Health, 28(12, Supplement 1), S133. https://doi.org/10.1016/j.jval.2025.09.547
  • Ecker, Hanne, Liang, Ava (2025). EE163 Cost-effectiveness analysis of ribociclib with endocrine therapy for treatment with premenopausal women with HR positive HER2 negative early breast cancer in the UK. Value in Health, 28(12, Supplement 1), S133. https://doi.org/10.1016/j.jval.2025.09.547
  • Federico, Augustovski, Chávez, Danitza, Haig, Madeleine, Main, Caitlin, Argento, Fernando, Colaci, Carla, Mills, Mackenzie, Alfie, Verónica, Pichon Riviere, Andrés & Alcaraz, Andrea et al (2025). A Delphi study on valuing DNA sequencing in oncology: a European stakeholder developed framework for assessing next generation sequencing and comprehensive genomic profiling diagnostics. EBioMedicine, 121, https://doi.org/10.1016/j.ebiom.2025.105947 picture_as_pdf
  • Forrest, Robin Jack (2025). The trade‑off between faster access and evidentiary certainty in the FDA’s Accelerated Approval of cancer drugs: empirical evidence on patient preferences and regulatory decision‑making [Doctoral thesis]. London School of Economics and Political Science. https://doi.org/10.21953/lse.00004962 picture_as_pdf
  • Jenei, Kristina, Booth, Christopher M. (2025). The delicate balancing act of accelerated approval for cancer medicines—speed, certainty, and benefit. JAMA network open, 8(3). https://doi.org/10.1001/jamanetworkopen.2025.2040 picture_as_pdf
  • Jenei, Kristina, Hahn, Georg, Kesselheim, Aaron S., Tibau, Ariadna (2025). Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992–2024). Journal of Cancer Policy, 45, https://doi.org/10.1016/j.jcpo.2025.100597 picture_as_pdf
  • Jenei, Kristina, Sullivan, Richard, Aggarwal, Ajay (2025). Policy and cancer care. In Treatment of Cancer, Eighth Edition (pp. 666-676). CRC Press. https://doi.org/10.1201/9781003433064-38 picture_as_pdf
  • Khanna, S., Sullivan, R., Lee, R., Krell, J., Jenei, K., Benjamin, D.J., Savage, P., Lythgoe, M. (2025). 2299P Access to oncology drugs in the UK are we falling behind Europe after Brexit? A retrospective analysis of regulatory performance and reimbursement for oncology drugs in the UK and Europe (2021-2025). Annals of Oncology, 36(Supplement 2), S1264. https://doi.org/10.1016/j.annonc.2025.08.2915
  • Naci, Huseyin, Shahzad, Mahnum, Murphy, Peter, Zhang, Yichen, Costa, Rebecca, Ross, Joseph S., Wagner, Anita K. (2025). Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation. BMJ Medicine, 4(1). https://doi.org/10.1136/bmjmed-2025-001934 picture_as_pdf
  • Schätz, L., Goulart, M., Cirillo, R., Hernandez, D., Peristeris, P., Poschenrieder, A., Papaioannou, P., Kanavos, P., la Fougère, C., Holzwarth, U. (2025). 2305P Are European healthcare systems prepared for a potential rapid rise in radioligand therapy eligible patient numbers? Annals of Oncology, 36(Supplement 2), S1267. https://doi.org/10.1016/j.annonc.2025.08.2921
  • Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology, 26(9), 1252 - 1260. https://doi.org/10.1016/S1470-2045(25)00329-8 picture_as_pdf
  • Zhang, Yichen, Li, Huangqianyu, Chen, Jinyu, Naci, Huseyin, Wagner, Anita K, Shi, Luwen, Guan, Xiaodong (2025). Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study. BMJ Evidence-Based Medicine, https://doi.org/10.1136/bmjebm-2025-113722 picture_as_pdf
    • 2024
  • Cherla, Avi, Kyriopoulos, Ilias, Pearcy, Pauline, Tsangalidou, Zoi, Hajrulahovic, Haris, Theodorakis, Pavlos, Andersson, Charlotte E., Mehra, Mandeep R., Mossialos, Elias (2024). Trends in avoidable mortality from cardiovascular diseases in the European Union, 1995–2020: a retrospective secondary data analysis. The Lancet Regional Health - Europe, 47, https://doi.org/10.1016/j.lanepe.2024.101079 picture_as_pdf
  • Figallo, Miguel, Delgado, María F., Gonzalez, Mauricio, Arenas, Adrián (2024). Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections. PLOS ONE, 19(11). https://doi.org/10.1371/journal.pone.0295730 picture_as_pdf
  • Forrest, Robin, Lagarde, Mylene, Aggarwal, Ajay, Naci, Huseyin (2024). Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. The Lancet Oncology, 25(12), 1635 - 1643. https://doi.org/10.1016/S1470-2045(24)00596-5 picture_as_pdf
  • Kanavos, Panos, Visintin, Erica, Angelis, Aris (2024). Use of the ESMO-magnitude of clinical benefit scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis. The Lancet Oncology, 25(12), 1644 - 1654. https://doi.org/10.1016/S1470-2045(24)00505-9 picture_as_pdf
  • Naci, Huseyin, Zhang, Yichen, Woloshin, Steven, Guan, Xiaodong, Xu, Ziyue, Wagner, Anita K. (2024). Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. The Lancet Oncology, 25(6), 760 - 769. https://doi.org/10.1016/S1470-2045(24)00152-9 picture_as_pdf
  • Shahzad, Mahnum, Naci, Huseyin, Esselen, Katharine M., Dottino, Joseph A., Wagner, Anita K. (2024). Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. Journal of Pharmaceutical Policy and Practice, 17(1). https://doi.org/10.1080/20523211.2024.2351003 picture_as_pdf
    • 2023
  • Anderson, Michael, Panteli, Dimitra, van Kessel, Robin, Ljungqvist, Gunnar, Colombo, Francesca, Mossialos, Elias (2023). Challenges and opportunities for incentivising antibiotic research and development in Europe. The Lancet Regional Health - Europe, 33, https://doi.org/10.1016/j.lanepe.2023.100705 picture_as_pdf
  • Dilley, James, Gentry-Maharaj, Aleksandra, Ryan, Andy, Burnell, Matthew, Manchanda, Ranjit, Kalsi, Jatinderpal, Singh, Naveena, Woolas, Robert, Sharma, Aarti & Williamson, Karin et al (2023). Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer – An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 179, 123 - 130. https://doi.org/10.1016/j.ygyno.2023.11.005 picture_as_pdf
  • Jenei, Kristina, Raymakers, Adam J.N., Bayle, Arnaud, Berger-Thürmel, Karin, Cherla, Avi, Honda, Kazunori, Jackson, Christopher C.G.A., Karikios, Deme, Trapani, Dario & Berry, Scott et al (2023). Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. The Lancet Oncology, 24(6), 624 - 635. https://doi.org/10.1016/S1470-2045(23)00175-4
  • Jentzsch, Valerie, Osipenko, Leeza, Scannell, Jack W., Hickman, John A. (2023). Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors. JAMA network open, 6(7), E2324977. https://doi.org/10.1001/jamanetworkopen.2023.24977 picture_as_pdf
  • Marti, Juan Luis Gomez, Wells, Jakob Z., Wells, Alan (2023). Statins as a secondary preventive agent for metastatic cancer. Journal of Thoracic Oncology, 18(11), e125 - e126. https://doi.org/10.1016/j.jtho.2023.07.027
    • 2022
  • Djamgoz, Mustafa B.A., Jentzsch, Valerie (2022). Integrative management of pancreatic Cancer (PDAC): emerging complementary agents and modalities. Nutrition and Cancer, 74(4), 1139 – 1162. https://doi.org/10.1080/01635581.2021.1934043 picture_as_pdf
  • Vokinger, Kerstin N., Hwang, Thomas J., Carl, David L., Laube, Yannic, Ludwig, Wolf Dieter, Naci, Huseyin, Kesselheim, Aaron S. (2022). Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. The Lancet Oncology, 23(4), 514 - 520. https://doi.org/10.1016/S1470-2045(22)00073-0
    • 2021
  • Burnell, Matthew, Gentry-Maharaj, Aleksandra, Skates, Steven J., Ryan, Andy, Karpinskyj, Chloe, Kalsi, Jatinderpal, Apostolidou, Sophia, Singh, Naveena, Dawnay, Anne & Woolas, Robert et al (2021). UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials, 22(1), p. 173. https://doi.org/10.1186/s13063-021-05125-8 picture_as_pdf
  • Fu, Mengyuan, Naci, Huseyin, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis, Wagner, Anita K. (2021). Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181(12), 1596 - 1604. https://doi.org/10.1001/jamainternmed.2021.5983
  • Kalsi, Jatinderpal K., Ryan, Andy, Gentry-Maharaj, Aleksandra, Margolin-Crump, Danielle, Singh, Naveena, Burnell, Matthew, Benjamin, Elizabeth, Apostolidou, Sophia, Habib, Mariam & Massingham, Susan et al (2021). Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials—an ovarian cancer exemplar. Trials, 22(1). https://doi.org/10.1186/s13063-020-04968-x picture_as_pdf
    • 2020
  • Angelis, Aris, Linch, Mark, Montibeller, Gilberto, Molina Lopez, Maria Teresa, Zawada, Anna, Orzel, Kinga, Arickx, Francis, Espin, Jaime, Kanavos, Panos (2020). Multiple criteria decision analysis for HTA across four EU member states: piloting the Advance Value Framework. Social Science & Medicine, 246, https://doi.org/10.1016/j.socscimed.2019.112595 picture_as_pdf
  • Cherla, Avi, Renwick, Matthew, Jha, Ashish, Mossialos, Elias (2020). Cost-effectiveness of cancer drugs: comparative analysis of the United States and England. EClinicalMedicine, 29-30, https://doi.org/10.1016/j.eclinm.2020.100625 picture_as_pdf
  • Dilley, James, Burnell, Matthew, Gentry-Maharaj, Aleksandra, Ryan, Andy, Neophytou, Christina, Apostolidou, Sophia, Karpinskyj, Chloe, Kalsi, Jatinderpal, Mould, Tim & Woolas, Robert et al (2020). Ovarian cancer symptoms, routes to diagnosis and survival – population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 158(2), 316 - 322. https://doi.org/10.1016/j.ygyno.2020.05.002 picture_as_pdf
  • Justo, Nahila, Nilsson, Jonas, Korytowsky, Beata, Dalen, Johan, Madison, Terri, McGuire, Alistair (2020). Retrospective observational cohort study on innovation in oncology and progress in survival how far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population? PLOS ONE, 15(5). https://doi.org/10.1371/journal.pone.0232669 picture_as_pdf
  • Pinto, Ashlyn, Naci, Huseyin, Neez, Emilie, Mossialos, Elias (2020). Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs. Value in Health, 23(3), 319-327. https://doi.org/10.1016/j.jval.2019.10.010 picture_as_pdf
  • Salas-Vega, Sebastian, Shearer, Emily, Mossialos, Elias (2020). Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Social Science & Medicine, 258, https://doi.org/10.1016/j.socscimed.2020.113042 picture_as_pdf
  • Smith, Claire Friedemann, Drew, Sarah, Ziebland, Sue, Nicholson, Brian D. (2020). Understanding the role of GPs' gut feelings in diagnosing cancer in primary care: a systematic review and meta-analysis of existing evidence. The British journal of general practice : the journal of the Royal College of General Practitioners, 70(698), e612 - e621. https://doi.org/10.3399/bjgp20X712301
    • 2017
  • Menon, Usha, McGuire, Alistair J., Raikou, Maria, Ryan, Andy, Davies, Susan K., Burnell, Matthew, Gentry-Maharaj, Aleksandra, Kalsi, Jatinderpal K., Singh, Naveena & Amso, Nazar N. et al (2017). The cost-effectiveness of screening for ovarian cancer results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer, 117(5), 619 - 627. https://doi.org/10.1038/bjc.2017.222
    • 2015
  • Maynou-Pujolras, Laia, Cairns, John (2015). Why do some countries approve a cancer drug and others don't? Journal of Cancer Policy, 4, 21-25. https://doi.org/10.1016/j.jcpo.2015.05.004
  • Menon, Usha, Ryan, Andy, Kalsi, Jatinderpal, Gentry-Maharaj, Aleksandra, Dawnay, Anne, Habib, Mariam, Apostolidou, Sophia, Singh, Naveena, Benjamin, Elizabeth & Burnell, Matthew et al (2015). Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening. Journal of Clinical Oncology, 33(18), 2062-2071. https://doi.org/10.1200/JCO.2014.59.4945
    • 2014
  • Aggarwal, Ajay, Sullivan, Richard (2014). Affordability of cancer care in the United Kingdom: is it time to introduce user charges? Journal of Cancer Policy, 2(2), 31-39. https://doi.org/10.1016/j.jcpo.2013.11.001
  • Warren, Emily, Footman, Katharine, Tinelli, Michela, McKee, Martin, Knai, Cecile (2014). Do cancer-specific websites meet patient's information needs? Patient Education and Counseling, 95(1), 126-136. https://doi.org/10.1016/j.pec.2013.12.013
    • 2011
  • Brar, Savtaj S., Seevaratnam, Rajini, Cardoso, Roberta, Law, Calvin, Helyer, Lucy, Coburn, Natalie G. (2011). A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer, Online, https://doi.org/10.1007/s10120-011-0087-4
    • 2010
  • Geitona, Mary, Kanavos, Panos (2010). Colocteral cancer management and prevention policies in Greece. European Journal of Health Economics, 10(Supp.1), 27-33. https://doi.org/10.1007/s10198-009-0193-y
  • Kanavos, Panos, Schurer, Willemien (2010). The burden of colorectal cancer: prevention, treatment and quality of services. European Journal of Health Economics, 10(Supp.1), 1-3. https://doi.org/10.1007/s10198-009-0200-3
  • Kanavos, Panos, Schurer, Willemien (2010). The dynamics of colorectal cancer management in 17 countries. European Journal of Health Economics, 10(Supp.1), 115-129. https://doi.org/10.1007/s10198-009-0201-2
  • Schurer, Willemien, Kanavos, Panos (2010). Colorectal cancer management in the United Kingdom: current practice and challenges. European Journal of Health Economics, 10(Supp.1), 85-90. https://doi.org/10.1007/s10198-009-0202-1
    • 2008
  • Kanavos, Panos, Schurer, Willemien, Owusu-Apenten, Candida, Sullivan, Richard (2008). Colorectal cancer in Europe and Australia: challenges and opportunities for the future. LSE Health, London School of Economics and Political Science.
  • Wordsworth, Sarah, Buchanan, J., Papanicolas, Irene, Taylor, J., Frayling, I., Tomlinson, I. (2008). Molecular testing for somatic mutations in common cancers: the views of UK oncologists. Journal of Clinical Pathology, 61(6), 761-765. https://doi.org/10.1136/jcp.2007.054510
  • Wordsworth, Sarah, Papanicolas, Irene, Buchanan, J., Frayling, I., Taylor, J., Tomlinson, I. (2008). Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories. Journal of Clinical Pathology, 61(3), 373-376. https://doi.org/10.1136/jcp.2007.048819
    • 2007
  • Sloggett, Andy, Young, Harriet, Grundy, Emily (2007). The association of cancer survival with four socioeconomic indicators: a longitudinal study of the older population of England and Wales 1981–2000. BMC Cancer, 7(20), 1-8. https://doi.org/10.1186/1471-2407-7-20
    • 2004
  • Grundy, Emily, Mayer, D., Young, H., Sloggett, Andy (2004). Living arrangements and place of death of older people with cancer in England and Wales: a record linkage study. British Journal of Cancer, 91(5), 907-912. https://doi.org/10.1038/sj.bjc.6602038
    • 2000
  • Blake, Peter, Evans, J. Grimley, Fallowfield, Lesley, Fentiman, Ian, Gosney, Margot, Grundy, Emily, Harper, Peter, Heath, Hazel, Heath, Iona & Khaw, Kay-Tee et al (2000). Position paper by the UKCCCR Elderly Cancer Patients in Clinical Trials Working Group. British Journal of Cancer, 82(1), 1-3. https://doi.org/10.1054/bjoc.1999.0866
  • Hutton, John (2000). Assessing the cost-effectiveness of imaging technology: recent results, problems and progress in the UK. European Radiology, 10(Supple), S427-S429. https://doi.org/10.1007/PL00014117
    • 1999
  • Dolan, Paul, Torgerson, D., Wolstenholme, J. (1999). Costs of breast cancer treatment in the United Kingdom. Breast, 8(4), 205-207. https://doi.org/10.1054/brst.1999.0035